Blood

Vol. 146, Issue Supplement 1 Issue Supplement 1 2025
8248
Articles

Articles in this Issue

Molecular determinants of therapeutic response to nivolumab in Relapsed/Refractory PTCL: An integrated multiomic study of A phase II investigator-initiated trial

Takeshi Sugio, Soyeong Jun, Hideki Goto et al. Nov 03, 2025 pp. 5414-5414 10.1182/blood-2025-5414

Abstract Background: Peripheral T-cell lymphomas (PTCL) display heterogeneous responses to immune checkpoint inhibitors, including rare dura...

Genomic clustering informs risk-adapted conditioning regimens in AML with pre-transplant deep remission: Augmented stratification beyond ELN-2022 criteria

Ruixin Li, Haixiao Zhang, Wenwen Guo et al. Nov 03, 2025 pp. 507-507 10.1182/blood-2025-507

Abstract Background: The composition of conditioning regimens are critical determinants of post-transplant outcomes. However, there remains...

Mortality trends in patients with co-occurring chronic kidney disease and venous thromboembolism in the United States: A 25-year CDC wonder analysis (1999–2023)

Amna Amjad, Abdullah Bin Usman, Nayanika Tummala et al. Nov 03, 2025 pp. 6244-6244 10.1182/blood-2025-6244

Abstract Introduction: Chronic kidney disease (CKD) patients face elevated venous thromboembolism (VTE) risk due to neph...

Musculoskeletal ultrasound evaluation of joint health status and bleeding phenotype in severe and non-severe hemophilia (A and B)

Jonathan Roberts, Rachel Zwilling, Sarah Kreitzer et al. Nov 03, 2025 pp. 301-301 10.1182/blood-2025-301

Abstract Introduction: People with hemophilia (PwH) A and B are known to have variable bleeding phenotypes, may have joint bleeding that is...

Allogeneic dual-target CD19/BCMA CAR T-cell therapy (QT-019B) for refractory autoimmune hemolytic anemia

Lele Zhang, Ruonan Li, Yucan Shen et al. Nov 03, 2025 pp. 5922-5922 10.1182/blood-2025-5922

Abstract Background Refractory autoimmune hemolytic anemia (rAIHA) is characterized by severe, life-threatening hemolysis, and conventional...

Regional, and hospital-level disparities in mortality and ICU-level care among hospitalized peripheral T-cell lymphoma patients: Insights from the 2022 national inpatient sample

Yoonhee Choi, Inae Park Nov 03, 2025 pp. 8028-8028 10.1182/blood-2025-8028

Abstract Background Peripheral T-cell lymphomas (PTCL) are a rare and aggressive subtype of non-Hodgkin lymphoma with poor overall survival...

Clinical disparities in enteropathy-associated T-cell lymphoma: A national cancer database study of 736 patients treated at academic and community cancer centers

Oscar Hinojosa, Supreet Kaur, Leyla Bojanini et al. Nov 03, 2025 pp. 5413-5413 10.1182/blood-2025-5413

Abstract I) Background Enteropathy-associated T-cell lymphoma (EATL) represents 3% of peripheral T-cell lymphomas. It co...

Clinical parameters and outcomes associated with genetic alterations in patients diagnosed with complement-mediated hemolytic uremic syndrome (CM-HUS): A single center experience

Hafez Abdullah, Mohammad Ali, Omar Abughanimeh Nov 03, 2025 pp. 3113-3113 10.1182/blood-2025-3113

Abstract Background Complement-mediated HUS (CM-HUS) is a rare thrombotic microangiopathy (TMA) caused by congenital or acquired dysregulatio...

Outcomes of haploidentical hematopoietic stem cell transplantation in low- and middle-income countries: A systematic review and meta-analysis.

Moazzam Shahzad, Muhammad Kashif Amin, Rehan Ishaque et al. Nov 03, 2025 pp. 7816-7816 10.1182/blood-2025-7816

Abstract Introduction: Haploidentical hematopoietic cell transplantation (haplo-HCT) has emerged as a critical alternati...

Study on the efficacy and safety of HDAC inhibitor combined with venetoclax and azacitidine in the treatment of adult T-ALL

Jiyi Fu, Boyue Zheng, Jun Wang et al. Nov 03, 2025 pp. 1579-1579 10.1182/blood-2025-1579

Abstract Background Acute T-ALL leukemia (T-ALL) is prone to primary drug resistance, induction failure, central infiltration, early recurre...

Proof-of-concept study of the CD39-blocking antibody JS019 in eosinophilic-associated disorders

Danqing Zhao, Huishan Sun, Jian Li et al. Nov 03, 2025 pp. 189-189 10.1182/blood-2025-189

Abstract Background CD39, an ectonucleotidase that hydrolyzes extracellular ATP to AMP, drives immunosuppressive adenosine accumulation and...

IMV101, a novel CD19-targeted In Vivo CAR T therapy exhibits potent efficacy and tolerable safety profiles in preclinical models

Shuangshuang Zhang, Yantao Li, Xiaojiang Fan et al. Nov 03, 2025 pp. 5875-5875 10.1182/blood-2025-5875

Abstract Background: Autologous CD19 CAR-T cell therapy has shown remarkable efficacy in B-cell hematologic malignancies, yet its widespread...

Decitabine enhances the cytotoxic effect of ruxolitinib in myeloproliferative neoplasms by targeting SR splicing factors

Qingmei Han, Rumeng Li, Bingbing Wen et al. Nov 03, 2025 pp. 7276-7276 10.1182/blood-2025-7276

Abstract Introduction:The Breakpoint Cluster Region–Abelson (BCR-ABL) negative myeloproliferative neoplasms (MPNs) are a group of chronic he...

Dual roles of proton pump inhibitors in estrogen-induced venous thromboembolism

Murat Yaman, Clayton Habiger, Jacqueline Lee et al. Nov 03, 2025 pp. 200-200 10.1182/blood-2025-200

Abstract Venous thromboembolism (VTE), including deep vein thrombosis and pulmonary embolism, is the third leading cause of cardiovascular m...

Resolvins modulate haematopoietic stem and progenitor cell dysfunction and neutrophil activation in sickle cell disease

Vishaka Gorur, Duco Koenis, Emmanuel Albuquerque-Souza et al. Nov 03, 2025 pp. 1148-1148 10.1182/blood-2025-1148

Abstract Chronic inflammation is characteristic of sickle cell disease (SCD), and the resulting neutrophil activation plays a significant ro...

Chronic myelomonocytic leukemia: Clinical outcomes from clinical trials submitted to the FDA over the past 25 years

Yanxia Li, Radhika Avadhani, dianne pulte et al. Nov 03, 2025 pp. 2073-2073 10.1182/blood-2025-2073

Abstract Introduction: Chronic myelomonocytic Leukemia (CMML) is a rare hematological malignancy with features of both m...

Sequential monitoring using NGS allows detection of ABL1 KD mutations in patients with chronic Phase CML: Results from the prospective calls trial

Ipek Baymul, Peter Edel, Sophie Jackson et al. Nov 03, 2025 pp. 2007-2007 10.1182/blood-2025-2007

Abstract Background BCR :ABL1 kinase domain (KD) mutations are...

Shift toward more naïve phenotype of the T cell compartment in patients with aggressive B cell non-Hodgkin lymphoma undergoing high-dose methotrexate therapy

Vanessa Ridder, Keven Hoerster, Sophie Nickel et al. Nov 03, 2025 pp. 4188-4188 10.1182/blood-2025-4188

Abstract Introduction: Immunotherapies such as bispecific antibodies (BsAbs) and chimeric antigen receptor T cell therap...

Autoimmunity against POLR3A and cytopenias in aplastic anemia and other bone marrow failure syndromes

Serhan Unlu, Kartik Lakhotiya, Mark Orland et al. Nov 03, 2025 pp. 4977-4977 10.1182/blood-2025-4977

Abstract Idiopathic aplastic anemia (IAA) is mediated by cytotoxic T-cells directed toward unrecognized antigen(s) on hematopoietic stem and...

Improved long-term tolerability and efficacy of asciminib-based combination therapies in newly diagnosed CML patients - the fascination trial.

Thomas Ernst, Philipp le Coutre, Martina Crysandt et al. Nov 03, 2025 pp. 903-903 10.1182/blood-2025-903

Abstract Introduction: “The Frontline asciminib in combination” - FASCINATION study (NCT03906292) is a multicenter, prospective, open-label,...

Evolution of joint health and physical activity in people with hemophilia A without factor VIII inhibitors switching to emicizumab prophylaxis: A second interim analysis of the BEYOND ABR study

Rebecca Kruse-Jarres, Giancarlo Castaman, Matteo Nicola Dario Di Minno et al. Nov 03, 2025 pp. 1285-1285 10.1182/blood-2025-1285

Abstract Background: Advances in hemophilia A (HA) treatment have led to lower bleeding rates (Srivastava et al. Haemophilia 2020), shifting...

Uncovering molecular trajectories in follicular lymphoma using hidden markov models of ctdna dynamics

Ana Jiménez Ubieto, Alejandro Martín-Muñoz, Davide Di Lernia et al. Nov 03, 2025 pp. 5322-5322 10.1182/blood-2025-5322

Abstract Circulating tumor DNA (ctDNA) is a valuable prognostic biomarker in follicular lymphoma (FL) frontline treatment, providing a minim...

GMP-compliant generation, expansion, and a preliminary safety evaluation of CMV-specific t cells using a closed system for post-transplant viral control

Luciana Marti, Mariana Kerbauy, Anita Silva et al. Nov 03, 2025 pp. 7651-7651 10.1182/blood-2025-7651

Abstract Despite advances in transplantation, recipients of allogeneic hematopoietic stem cell transplantation (allo-HSCT) remain at high ri...

Comparative analysis of severe infection risk and survival outcomes in DLBCL patients treated with CAR T-cell therapy versus standard chemoimmunotherapy: Insights from real-world data

Nancy Lunney, Kausik Maiti MD, Chris Learn et al. Nov 03, 2025 pp. 8032-8032 10.1182/blood-2025-8032

Abstract Background: Diffuse large B-cell lymphoma (DLBCL) treatments, including standard chemoimmunotherapy (R-CHOP/R-EPOCH) and CAR T-cell...

This is hitting the heparin sweet spot: Here is a retrospective analysis of investigating and optimizing aPTT monitoring for safety and efficacy during intravenous heparin infusion

Nang Inn Pun Kham, Amogh Killedar, Hussein Al-Dabbagh et al. Nov 03, 2025 pp. 6674-6674 10.1182/blood-2025-6674

Abstract Introduction Unfractionated heparin (UFH) remains a cornerstone in the treatment of thromboembolic conditions such as deep vein thr...

All Issues

Journal Info

Publisher Elsevier BV
ISSN 0006-4971
E-ISSN 1528-0020
Subject Health Sciences
Language English
View Full Journal Page